Trials / Not Yet Recruiting
Not Yet RecruitingNCT06474455
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
A Phase IB/II, Open-Label, Multicentre Clinical Study to Evaluate the Safety, Tolerability and Efficacy of SHR-9839 for Injection in Combination With Other Therapies in Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-9839 ；SHR-A2009 | SHR-9839 combined with SHR-A2009 |
| DRUG | SHR-9839 ； SHR-A1921 | SHR-9839 combined with SHR-A1921 |
| DRUG | SHR-9839 ； pemetrexed ；carboplatin | SHR-9839 combined with pemetrexed + carboplatin |
| DRUG | SHR-9839 ； Almonertinib | SHR-9839 combined with Almonertinib |
Timeline
- Start date
- 2024-06-01
- Primary completion
- 2026-06-01
- Completion
- 2027-06-01
- First posted
- 2024-06-25
- Last updated
- 2024-06-25
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06474455. Inclusion in this directory is not an endorsement.